Clinical Trial Update: A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise [Phase 3]

View source ↗

Summary

Phase 3 results update for dapagliflozin (BMS-512148) in Asian patients with Type 2 diabetes not well controlled by diet and exercise.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2017-02-06